The global Digital PCR Market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East Africa. In 2022, North America accounted for the largest share of the market, followed by Europe. Market growth in North America is driven by the increased adoption of innovative and novel genomic analysis qPCR and dPCR products, the availability of RD funding for genomics research, and the expanding use of PCR techniques in clinical diagnostics and forensics.

Growth in the Asia Pacific market is primarily due to the ongoing expansion and modernization of the healthcare infrastructure in emerging Asian countries, the increasing number of research projects in China, India, and Japan in the field of genomics and oncology, the rising trend of clinical research being outsourced to Asia-based CROs by leading drug manufacturing companies, and continuous government support for genomics-based research activities in emerging Asia Pacific countries.

NORTH AMERICA

The North American Digital PCR Market comprises the US and Canada. North America is a mature market with a high penetration of qPCR and dPCR technologies among key end users (including hospitals, diagnostic centers, research laboratories, pharmaceutical biotechnology companies, and forensic laboratories), robust genomics research infrastructure, and a strong market presence of genomic product manufacturers. Market growth in North America is driven by the rising number of genome-based drug development activities undertaken by US-based Pharmaceutical Biotechnology Companies, the increasing public-private funding and research grants to develop innovative dPCR and qPCR technologies, and the growing target patient base (coupled with the increasing patient emphasis on early and effective disease diagnosis). In October 2022, Roche received FDA clearance for a COVID-19 PCR test for use on cobas 6800/8800 Systems. The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high-throughput platform to receive FDA 510(k) clearance.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204

However, the high product costs associated with dPCR instruments, the continuous decline in the average prices of qPCR reagents (owing to the entry of SMEs for PCR reagent manufacturing), the stringent regulations governing the commercialization of qPCR and dPCR products in the US, and the technical limitations of dPCR and qPCR are the major factors restraining the growth of this market.

US

High incidence of chronic and genetic diseases to drive market

The US holds a dominant share of the North American Digital PCR Market due to factors such as the high incidence of chronic and genetic diseases (coupled with the rising geriatric population), the growing adoption of qPCR and dPCR techniques in research and academia, significant public-private funding in the field of genome analysis, and the strong presence of major pharmaceutical biotechnology companies in the country.

The US is a well-developed market for genome analysis techniques that are primarily used in clinical applications by healthcare professionals (such as pathogen detection, disease diagnosis, and DNA identification) and research applications by life science researchers (such as genomics and molecular research).

Get 10% Free Customization on This Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=174151204

CANADA

Government initiatives in support of genomics research to drive market in Canada

Canada accounted for a modest share of the North American Digital PCR Market in 2022. Ongoing government initiatives to support life science research, the availability of research funding for genomic and clinical research, the increasing incidence of infectious diseases, and the growing number of clinical diagnostic tests (that include the use of PCR techniques) are the major factors driving market growth in Canada. The rapidly growing research industry in Canada, coupled with the increasing availability of funding to support ongoing research activities, is expected to provide additional growth opportunities to market players.

 EXECUTIVE SUMMARY

    FIGURE 9 GLOBAL REAL-TIME PCR PRODUCTS SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 GLOBAL DIGITAL PCR PRODUCTS SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 GLOBAL REAL-TIME PCR MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 GLOBAL DIGITAL PCR MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GLOBAL REAL-TIME PCR MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 GLOBAL DIGITAL PCR MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 DIGITAL PCR MARKET: GEOGRAPHICAL SNAPSHOT

DIGITAL PCR  MARKET, BY REGION

NORTH AMERICA

          FIGURE 25 NORTH AMERICA: DIGITAL PCR MARKET SNAPSHOT
          TABLE 251 NORTH AMERICA: DPCR QPCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 252 NORTH AMERICA: DPCR QPCR MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
          TABLE 253 NORTH AMERICA: QPCR MARKET, BY PRODUCT SERVICE, 2021–2028 (USD MILLION)
          TABLE 254 NORTH AMERICA: DIGITAL PCR MARKET, BY PRODUCT SERVICE, 2021–2028 (USD MILLION)
          TABLE 255 NORTH AMERICA: DPCR INSTRUMENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 256 NORTH AMERICA: QPCR MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 257 NORTH AMERICA: QPCR CLINICAL APPLICATIONS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 258 NORTH AMERICA: DPCR MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 259 NORTH AMERICA: DPCR CLINICAL APPLICATIONS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 260 NORTH AMERICA: QPCR MARKET, BY END USER, 2021–2028 (USD MILLION)
          TABLE 261 NORTH AMERICA: DIGITAL PCR MARKET, BY END USER, 2021–2028 (USD MILLION)

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]